




TransIT[®]-BrCa Transfection Reagent

The first reagent designed and optimized for breast cancer cell lines.

- **Broad Spectrum DNA Delivery** - Achieve high expression levels in multiple breast cancer cell types.
- **Formulated for Low Cellular Toxicity** - Maintain cell density and reduce experimental biases due to toxicity.
- **Superior Transfection Efficiency** - *TransIT[®]-BrCa* outperforms Lipofectamine[®] 2000 in numerous breast cancer cell lines.

TransIT[®]-BrCa Transfection Reagent yields high efficiency plasmid DNA transfection in breast cancer cell lines.

For experimental details, please visit:
www.mirusbio.com



Delivery by

Mirus.


www.mirusbio.com



Available in Canada from...

MJS
BioLynx
INC.

1-888-593-5969 • www.biolynx.ca • tech@biolynx.ca



TransIT®-BrCa Transfection Reagent Exhibits Higher Luciferase Expression in Breast Cancer Cells Compared to Other Transfection Reagents. Breast cancer cell lines were transfected with a luciferase expression plasmid at the reagent-to-DNA ratios indicated. Transfections were performed in 96-well plates using 0.1 µg of plasmid DNA per well. Luciferase expression was measured at 24 hours post-transfection using a standard assay. Error bars represent the standard deviation of triplicate wells.

TransIT®-BrCa Transfection Reagent



PRODUCT NO.	QUANTITY
MIR 5504	0.4 ml
MIR 5500	1 ml
MIR 5505	5 x 1 ml
MIR 5506	10 x 1 ml

Prove it to Yourself with a **FREE SAMPLE**



Reagent Agent®

Transfection reagent recommendations based on citations, customer feedback, and in-house transfection data. Find the ideal delivery solution for your experiment: www.mirusbio.com/RA

Lit. No 0916135

©2016 All rights reserved. Mirus Bio LLC.
TransIT® is a registered trademark of Mirus Bio LLC. Reagent Agent is a service mark of Mirus Bio LLC.
FuGENE® is a registered trademark of Fugent LLC. Lipofectamine® is a registered trademark of Life Technologies Corporation



1-888-593-5969 • www.biolynx.ca • tech@biolynx.ca